New York State Teachers Retirement System Buys 5,804 Shares of DexCom, Inc. (NASDAQ:DXCM)

New York State Teachers Retirement System raised its stake in DexCom, Inc. (NASDAQ:DXCM) by 1.6% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 366,308 shares of the medical device company’s stock after buying an additional 5,804 shares during the quarter. New York State Teachers Retirement System owned 0.09% of DexCom worth $24,557,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in DXCM. Crewe Advisors LLC bought a new position in shares of DexCom during the first quarter worth $29,000. Migdal Insurance & Financial Holdings Ltd. acquired a new stake in DexCom during the 2nd quarter worth $25,000. Sachetta LLC raised its stake in DexCom by 255.2% during the 2nd quarter. Sachetta LLC now owns 238 shares of the medical device company’s stock worth $27,000 after buying an additional 171 shares during the period. DT Investment Partners LLC grew its stake in DexCom by 492.2% in the second quarter. DT Investment Partners LLC now owns 379 shares of the medical device company’s stock valued at $43,000 after acquiring an additional 315 shares during the period. Finally, RiverPark Advisors LLC acquired a new position in DexCom in the first quarter valued at about $55,000. Institutional investors own 97.75% of the company’s stock.

Wall Street Analyst Weigh In

DXCM has been the topic of several recent analyst reports. Sanford C. Bernstein lifted their price objective on DexCom from $82.00 to $86.00 and gave the company an “outperform” rating in a report on Friday, October 25th. JPMorgan Chase & Co. upped their price target on shares of DexCom from $75.00 to $85.00 and gave the company a “neutral” rating in a report on Friday, October 25th. Piper Sandler restated an “overweight” rating and set a $90.00 price objective on shares of DexCom in a report on Monday, August 26th. Stifel Nicolaus boosted their price objective on shares of DexCom from $90.00 to $100.00 and gave the company a “buy” rating in a research report on Friday, August 23rd. Finally, Wells Fargo & Company increased their target price on DexCom from $80.00 to $90.00 and gave the stock an “overweight” rating in a report on Friday, October 25th. Six analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, DexCom presently has a consensus rating of “Moderate Buy” and a consensus target price of $104.59.

Insider Buying and Selling

In other DexCom news, COO Jacob Steven Leach sold 746 shares of the stock in a transaction on Monday, September 9th. The shares were sold at an average price of $69.15, for a total value of $51,585.90. Following the completion of the sale, the chief operating officer now owns 264,915 shares in the company, valued at $18,318,872.25. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. In other DexCom news, COO Jacob Steven Leach sold 746 shares of the company’s stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $69.15, for a total value of $51,585.90. Following the sale, the chief operating officer now owns 264,915 shares in the company, valued at $18,318,872.25. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Sadie Stern sold 426 shares of DexCom stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $69.15, for a total value of $29,457.90. Following the transaction, the executive vice president now owns 75,451 shares of the company’s stock, valued at $5,217,436.65. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.30% of the stock is owned by corporate insiders.

DexCom Trading Down 1.8 %

Shares of DexCom stock opened at $70.48 on Friday. The stock has a market cap of $27.53 billion, a P/E ratio of 42.20, a P/E/G ratio of 2.26 and a beta of 1.18. The company has a quick ratio of 2.48, a current ratio of 2.82 and a debt-to-equity ratio of 1.00. DexCom, Inc. has a 12-month low of $62.34 and a 12-month high of $142.00. The business’s 50 day moving average is $69.92 and its 200-day moving average is $96.37.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.